



## ASX RELEASE

### **Peplin takes steps to secure manufacturing plant**

**9 October 2006: Peplin Limited (ASX:PEP)** has initiated proceedings to secure its tenancy of the J H Aylward manufacturing facility in Southport, Queensland.

The manufacturing facility is Peplin's recently commissioned and licensed facility for the production of PEP005, the active ingredient in PEP005 Topical, its proprietary product being developed for the treatment of actinic (solar) keratosis and basal cell carcinoma, the most common form of skin cancer. The facility was opened on 20 July 2006 and is currently producing PEP005.

On 30 September 2004 Peplin contracted an independent engineering firm to design, build and operate the facility. Peplin has exercised its option to step in and operate the facility independently going forward. The contractor has disputed Peplin's right and the facility presently operates under an informal extension of the now expired operating agreement.

Peplin expects court proceedings to be concluded expeditiously and in its favour. Peplin has adequate supplies of PEP005 manufactured under GMP for its current actinic keratosis and pending basal cell carcinoma phase IIb clinical trials and its ongoing pre-clinical studies. Accordingly it does not expect the current litigation to cause an interruption or delay to its PEP005 Topical development program.

#### **Further information:**

Michael Aldridge

Managing Director & CEO

Tel: 07-3250 1200

[michael.aldridge@peplin.com](mailto:michael.aldridge@peplin.com)

**About Peplin**

Peplin is focused on the development and commercialisation of prescription human therapeutic products for the treatment of cancer. Its lead compound is PEP005, the first in a new class of investigational agents. Peplin's lead product is PEP005 Topical, which is being studied in clinical trials for the treatment of actinic keratosis (AK) (a pre-cancerous lesion) and non-melanoma skin cancer (NMSC). PEP005 Topical works by a powerful mode of action, directly killing most cancer cells and then recruiting and activating the local immune system to clean-up these dead cancer cells and kill any remaining cancer cells. PEP005 Topical is potentially a rapidly acting and cosmetically attractive non-surgical topical treatment for AK and NMSC. Peplin's product development activities are supported by the Australian Federal Government under its Pharmaceuticals Partnerships Program.

Peplin's earlier stage pipeline is targeted at leukemia (a blood borne cancer) using its lead compound PEP005 in an intravenous formulation (PEP005 IV) and bladder cancer using an intracavitary or intravesical formulation (PEP005 IC). PEP005 has demonstrated selective and potent anti-leukemia activity in pre-clinical disease models. PEP005 induces apoptosis in leukemia cells via the activation of PKC delta. Peplin holds global proprietary rights for PEP005 Topical and other therapeutic applications of PEP005. Its research portfolio of EPUFA compounds opens additional potential opportunities in cancer and pain.